Jacoby GA

Featured in: Favicon

onlinelibrary.wiley.com Favicon

academic.oup.com

Articles

Evolving resistance landscape in gram‐negative pathogens: An update on β‐lactam and β‐lactam‐inhibitor treatment combinations for carbapenem‐resistant organisms

Jul 1, 2024 | accpjournals.onlinelibrary.wiley.com | Christina Koenig |Joseph L. Kuti |Jacoby GA

CONFLICT OF INTEREST STATEMENT J.L.K. reports grants from Merck & Co, Inc, Shionogi, Entasis, the United States Food and Drug Administration, Biomeriuex, Roche, consulting fees and payment or honoraria for lectures from Shionogi. C.K. has received consulting fees and honoraria for lectures from Shionogi, Pfizer and Gilead, and reports grants from the DAMP and Joachim Herz Foundations. REFERENCES 1, , , .
In vitro activity of cefepime/taniborbactam and comparator agents against Gram-negative bacterial bloodstream pathogens recovered from patients with cancer

Apr 10, 2024 | academic.oup.com | Jacoby GA

Patients with cancer are prone to develop frequent bacterial infections, especially during chemotherapy-induced neutropenia.
What are the optimal pharmacokinetic/pharmacodynamic targets for β-lactamase inhibitors? A systematic review

Mar 9, 2024 | academic.oup.com | Jacoby GA

β-Lactam (BL) antibiotics are one of the widely used classes of antimicrobials to battle the war against bacterial infections.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →